Horizon Therapeutics PLC (NASDAQ:HZNP) EVP Irina Konstantinovsky sold 17,838 shares of Horizon Therapeutics stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $26.70, for a total value of $476,274.60. Following the completion of the sale, the executive vice president now owns 44,819 shares in the company, valued at approximately $1,196,667.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of HZNP stock traded down $0.09 on Friday, hitting $26.34. The stock had a trading volume of 838,735 shares, compared to its average volume of 1,792,526. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.20 and a quick ratio of 2.12. The firm has a market capitalization of $4.93 billion, a P/E ratio of 14.39, a P/E/G ratio of 1.55 and a beta of 0.77. Horizon Therapeutics PLC has a 1 year low of $16.56 and a 1 year high of $29.44. The company’s 50 day moving average price is $26.34 and its 200-day moving average price is $25.61.
Horizon Therapeutics (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.14. The firm had revenue of $320.60 million for the quarter, compared to the consensus estimate of $296.27 million. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.48 EPS. On average, equities analysts forecast that Horizon Therapeutics PLC will post 1.6 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HZNP. FMR LLC grew its stake in Horizon Therapeutics by 165.1% during the 1st quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock worth $137,575,000 after purchasing an additional 3,242,071 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Horizon Therapeutics by 1,910.0% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock worth $40,249,000 after purchasing an additional 1,589,614 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Horizon Therapeutics during the 1st quarter worth $27,663,000. Price T Rowe Associates Inc. MD grew its stake in Horizon Therapeutics by 1,774.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock worth $26,508,000 after purchasing an additional 1,042,969 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Horizon Therapeutics by 11.4% during the 2nd quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock worth $210,628,000 after purchasing an additional 896,500 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have commented on the company. Piper Jaffray Companies set a $33.00 target price on Horizon Therapeutics and gave the company a “buy” rating in a research report on Monday, August 26th. TheStreet downgraded Horizon Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, June 10th. BMO Capital Markets upgraded Horizon Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $29.00 to $36.00 in a report on Wednesday, August 14th. BidaskClub downgraded Horizon Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 6th. Finally, Cowen set a $35.00 price objective on Horizon Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $33.00.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
See Also: Why are trading ranges significant?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.